2篇
您的检索式：作者名="Yaxu Zheng"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | First Imported Case of SARS-CoV-2 Omicron Subvariant BA.5—Shanghai Municipality,China,May 13,2022显示文摘On April 27,2022,an international flight KL857 from Amsterdam,the Netherlands arrived at Pudong International Airport,Shanghai Municipality.Passengers were transferred to the quarantine hotel for a routine 14-day medical observation in Songjiang District and regularly tested for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).One of the passengers(a 37-year-old Chinese male)was reported positive and diagnosed as a mild case on April 29.The case set out from Uganda(flight KL535)on April 25 and transferred at Amsterdam,the Netherlands on April 26 and Seoul,the Republic of Korea(KL857)on April 27.The patient has been vaccinated in four doses against coronavirus disease 2019(COVID-19)(Beijing Institute of Biological Products Co.,Ltd)in China and Uganda.After diagnosis,he was transferred to Shanghai Public Health Clinical Center for treatment.He recovered after treatment and was discharged on May 12. | Hui Jiang Changcheng Wu Wenbo Xu Hongyou Chen Fanghao Fang Min Chen Chaonan Wang Lingyue Yuan Huanyu Wu Zheng Teng Jinyuan Guo Yaxu Zheng Xihong Lyu Xuefei Qiao Guizhen Wu Wenjie Tan Xi Zhang | 2022 | China CDC weekly2022，4，30： | 10 |
| 2 | Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein(QPCTL)with antitumor efficacy显示文摘Dear Editor,Immune checkpoint therapies manipulating the immune system to eliminate tumor cells have shown remarkable clinical efficacy in treating various cancers.CD47,an emerging efficient immune checkpoint,is crucial for cancer cells to evade macrophagemediated phagocytosis by interaction with signal-regulatory proteinα(SIRPα).Antibodies blocking the CD47/SIRPαinteraction have been effective to promote macrophage-mediated phagocytosis in various types of cancer in mice and humans.CD47 is not only highly expressed in tumor cells,but also normal cells,such as red blood cells(RBCs).Thus,during clinical trials involving cancer patients,anti-CD47 antibodies may promote the macrophagesmediated phagocytosis of RBCs,ultimately inducing undesirable anemia side effects.In contrast,small molecule inhibitors interrupting CD47/SIRPαaxis have shown potential to overcome the anemia,possibly due to their lower immunogenicity and shorter half-life compared to antibodies.1 Hence,developing the novel strategies,especially those without the anemia side effect,to intervene in CD47/SIRPαinteraction will benefit cancer immunotherapy. | Lei Yu Pengcheng Zhao Yaoliang Sun Zening Zheng Wenhao Du Lishan Zhang Yaxu Li Longyan Xie Shilin Xu Ping Wang | 2024 | Signal Transduction and Targeted Therapy2024，9，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员